Study: NCT05617885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Tablet administered orally, per protocol, 2 x daily. Darolutamide is an orally administered molecular drug therapy that blocks the action of testosterone, the male sex hormone which can stimulate growth of prostate cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Tablet administered orally, per protocol, 2 x daily. Abemaciclib is an orally administered molecular drug therapy that is called a CDK4/6 inhibitor. CDK4 and CDK6 are enzymes that are involved in helping healthy and cancerous cells divide and blocking these enzymes can stop cancerous cells from growing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNRH-A Leuprolide Acetate
Description: Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNRH-A Leuprolide Acetate
Description: Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNRH-A Leuprolide Acetate
Description: Administered via intramuscular injection, per standard of care. GnRH agonist is a hormonal therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNRH-A Goserelin
Description: Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNRH-A Goserelin
Description: Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNRH-A Goserelin
Description: Administered via subcutaneous injection, per standard of care. GnRH agonist is a hormonal therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Administered via subcutaneous injection, per standard of care. GnRH antagonist is a hormonal therapy drug.